BioCryst Pharmaceuticals, Inc. (BCRX)

US — Healthcare Sector
Peers: AUPH  BBIO  ANVS  DVAX  AGEN  INO  ACAD 

Automate Your Wheel Strategy on BCRX

With Tiblio's Option Bot, you can configure your own wheel strategy including BCRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BCRX
  • Rev/Share 2.4104
  • Book/Share -2.1636
  • PB -4.1044
  • Debt/Equity -1.7591
  • CurrentRatio 2.9247
  • ROIC 0.1005

 

  • MktCap 1858140000.0
  • FreeCF/Share -0.1306
  • PFCF -68.0962
  • PE -34.69
  • Debt/Assets 1.6561
  • DivYield 0
  • ROE 0.1143

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation BCRX Cantor Fitzgerald -- Overweight -- $20 April 29, 2025
Initiation BCRX Wedbush -- Outperform -- $15 Feb. 25, 2025

News

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
BCRX
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025.

Read More
image for news BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

About BioCryst Pharmaceuticals, Inc. (BCRX)

  • IPO Date 1994-03-04
  • Website https://www.biocryst.com
  • Industry Biotechnology
  • CEO Jon P. Stonehouse
  • Employees 580
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.